64Cu-NODAGA-CANF for Atherosclerosis
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical trial is to determine the biodistribution, safety, and calculate the radiation dosimetry of the novel atherosclerotic PET imaging radiotracer, 64Cu-NODAGA-CANF, in normal healthy adult volunteers.
Participants will receive a single intravenous administration of 64Cu-NODAGA-CANF and then undergo PET-CT imaging at various time points following injection. Safety will be assessed through evaluation of vital signs, clinical laboratory tests, physical examination, and electrocardiograms (EKGs). Telephone follow-up will occur 2-3 days after discharge.
Are You a Good Fit for This Trial?
This trial is for healthy adults who do not have any major health problems. Participants should be willing to undergo PET-CT scans and follow-up checks after receiving the imaging agent.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- 64Cu-NODAGA-CANF
Trial Overview
The study tests a new PET scan tracer called 64Cu-NODAGA-CANF, given by IV injection, to see how it spreads in the body and if it's safe. Volunteers will get one dose and several scans afterward.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Healthy adult normal volunteers will receive a single intravenous (IV) injection of less than 4 mCi of 64Cu-NODAGA-CANF followed by PET-CT imaging at 3 or 4 time points up to 48 hours post-injection (30-60 minutes, 2-6 hours, 18-24 hours and 40-48 hours).
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.